Dyax (DYAX) Higher After Competing Drug Fails to Hit Endpoint
Tweet Send to a Friend
Dyax Corp. (Nasdaq: DYAX) is 15% higher in after-hours action. According to a representative from the company, a competing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


